Conversion to sirolimus for chronic allograft dysfunction: Long-term results confirm predictive value of proteinuria

Transplant International

Volumn 21, Issue 2, 2008, Pages 152-155

  Diekmann, Fritz ^a,b   Budde, Klemens ^a   Slowinski, Torsten ^a   Oppenheimer, Federico ^b   Fritsche, Lutz ^a   Neumayer, Hans H ^a   Campistol, Josep M ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Calcineurin inhibitor; Chronic allograft dysfunction; Mammalian target of rapamycin inhibitor; Proteinuria; Rapamycin; Sirolimus; Toxicity

Indexed keywords

CALCINEURIN INHIBITOR; RAPAMYCIN;

ADULT; AGE; AGED; ARTICLE; CREATININE CLEARANCE; DRUG SUBSTITUTION; EVALUATION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HISTOLOGY; HUMAN; HUMAN TISSUE; INTOXICATION; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEINURIA; RISK FACTOR; SURVIVAL;

ADULT; AGED; CALCINEURIN; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROTEINURIA; SIROLIMUS;

EID: 38049110352     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2007.00592.x     Document Type: Article

References (10)

1. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi B. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002 346 : 580.
2. Dudley C, Pohanka E, Riad H, et al. Mycophenolate mofetil substitution for cyclosporine A in renal transplant recipients with crhonic progressive allograft dysfunction: The "Creeping Creatinine" Study. Transplantation 2005 79 : 466.
3. Watson CJE, Firth J, Williams PF, et al. A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation. Am J Transpl 2005 5 : 2496.
4. Bumbea V, Kamar N, Ribes D, et al. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant 2005 20 : 2517.
5. Morelon E, Kreis H. Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience. Transplant Proc 2003 35 (Suppl. 3A 52S.
6. Diekmann F, Budde K, Oppenheimer F, Fritsche L, Neumayer HH, Campistol JM. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 2004 4 : 1869.
7. Sennesael JJ, Bosmans JL, Bogers JP, Verbeelen D, Verpooten GA. Conversion from cyclosporine to sirolimus in stable renal transplant recipients. Transplantation 2005 80 : 1578.
8. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004 4 : 1289.
9. Nankivell BJ, Borrows RJ, Chir B, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003 349 : 2326.
10. Anonymous. Univariate and multivariate analyses of factors affecting renal allograft function after conversion from calcineurin inhibitor (ci)- to sirolimus (srl)-based immunosuppression: results from the multicenter convert trial. Transplantation 2006 82 (1 Suppl. 2 412.